Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accounts Payables: 2019-2025

Historic Accounts Payables for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $3.6 million.

  • Biodesix's Accounts Payables rose 42.57% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 42.57%. This contributed to the annual value of $2.2 million for FY2024, which is 25.09% down from last year.
  • Latest data reveals that Biodesix reported Accounts Payables of $3.6 million as of Q3 2025, which was up 21.66% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Accounts Payables registered a high of $3.7 million during Q1 2021, and its lowest value of $1.2 million during Q2 2021.
  • Over the past 3 years, Biodesix's median Accounts Payables value was $2.9 million (recorded in 2025), while the average stood at $2.8 million.
  • In the last 5 years, Biodesix's Accounts Payables slumped by 81.46% in 2021 and then skyrocketed by 105.57% in 2024.
  • Over the past 5 years, Biodesix's Accounts Payables (Quarterly) stood at $1.7 million in 2021, then climbed by 1.38% to $1.7 million in 2022, then spiked by 73.83% to $2.9 million in 2023, then declined by 25.09% to $2.2 million in 2024, then soared by 42.57% to $3.6 million in 2025.
  • Its Accounts Payables was $3.6 million in Q3 2025, compared to $3.0 million in Q2 2025 and $2.9 million in Q1 2025.